A meeting was held in Bishkek organized as part of the UNIDO mission — international UN experts on industrial development. The event was attended by representatives from the Ministry of Economy, the Ministry of Health, and domestic pharmaceutical companies, reports the press service of the Ministry of Economy of Kyrgyzstan.
Among the issues discussed were key priorities for the development of the pharmaceutical industry, the requirements of the Eurasian Economic Union for GMP standards, as well as mechanisms to support the modernization of production in this sector.
In addition, a working seminar was held on the topic "Strengthening compliance of Kyrgyzstan's pharmaceutical industry with good manufacturing practice requirements: assessment results, international standards, and next steps." Participants of the seminar included representatives of government agencies, pharmaceutical product manufacturers, and international experts.
UNIDO experts presented the results of the assessment of Kyrgyz pharmaceutical enterprises' compliance with GMP standards, as well as an overview of international practices and regulations in this area.
During the discussions, emphasis was placed on the importance of implementing GMP standards to improve the quality and safety of medicines, as well as to expand the export opportunities of local producers, especially in the markets of the Eurasian Economic Union countries.
Furthermore, participants were presented with the results of a survey of pharmaceutical companies conducted by UNIDO, which helped determine the current level of the industry's readiness to implement GMP standards and identify key areas for further development and modernization of production processes.
As part of this mission, UNIDO experts also plan to conduct technical visits to the country's pharmaceutical enterprises to assess the current state of GMP standards implementation and identify needs for technical and expert support.
The implementation of this initiative is expected to contribute to improving the quality and safety of medicines, developing the national pharmaceutical industry, and increasing the export potential of domestic producers.
